Ascendis Pharma A/S
Ascendis Pharma is a Danish biotechnology company developing treatments using its TransCon drug-development platform, which is designed to enable specific therapeutic delivery characteristics. Its programs include endocrine diseases and other serious conditions. The issuer announced an important security-structure change in April 2026: Nasdaq ticker ASND continued, but trading changed from American depositary shares to ordinary shares. This directory records the current security type rather than describing ASND as an ongoing ADS listing.
Company at a glance
Corporate information
- Company entity
- Ascendis Pharma A/S
- Headquarters / principal office
- Denmark
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://ascendispharma.com
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq: ASND
TransCon · long-acting-therapeutics · protein-therapeutics
endocrinology · oncology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Ascendis Pharma is a Danish biotechnology company developing treatments using its TransCon drug-development platform, which is designed to enable specific therapeutic delivery characteristics. Its programs include endocrine diseases and other serious conditions. The issuer announced an important security-structure change in April 2026: Nasdaq ticker ASND continued, but trading changed from American depositary shares to ordinary shares. This directory records the current security type rather than describing ASND as an ongoing ADS listing.
Business, technology & evidence
- SecuritiesNasdaq: ASND
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Ascendis Pharma A/S ↗Ascendis Pharma A/S ·
- Official issuer and R&D disclosure · Ascendis Pharma A/S ↗Ascendis Pharma A/S ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.